Stock report · Delisted · Nasdaq
Omega Therapeutics Inc (OMGA)
0.05USD Delisted Final close · Apr 28, 2025
OMGA no longer trades. Omega Therapeutics was delisted from the Nasdaq in April 2025.
All prices on this page are historical. The last trade was on April 28, 2025, at $0.05.
OMGA stock price history
Final trading statistics
- Final close
- $0.05
- Final trading day
- Apr 28, 2025
- Market cap at delisting
- $7.90M
- Shares outstanding
- 55.37M
- Final 52-week range
- $0.01 – $3.00
- Avg. volume (final 3 mo.)
- 8,803,508
- All-time high
- $29.38 · Oct 2021
- All-time low
- $0.01 · Mar 2025
- Return since IPO
- -99.7%
- Beta
- 1.64
- Book value / share
- $0.21
- Price / book
- 0.23
About Omega Therapeutics Inc
Omega Therapeutics was a clinical-stage biotechnology company. Its OMEGA platform aimed to control epigenetic processes so that abnormal gene expression could be brought back into range without changing the underlying DNA or RNA sequence.
Its programs included OTX-2002 for liver cancer (hepatocellular carcinoma) and OTX-2101 for non-small cell lung cancer. It also worked on omega epigenomic controllers (OECs) for inflammatory lung diseases such as neutrophilic asthma and acute respiratory distress syndrome, idiopathic pulmonary fibrosis, liver regeneration, corneal injury in diabetic and other patients, and alopecia, as well as skin, cancer and rheumatology uses.
The company was incorporated in 2016 and based in Cambridge, Massachusetts. It filed for Chapter 11 in Delaware on February 10, 2025. Its stock was delisted from the Nasdaq in April 2025, with the last trade on April 28, 2025 at $0.05.
- Exchange (former)
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Cambridge, MA
- Employees
- 93
- IPO date
- July 30, 2021
- Delisted
- April 28, 2025
- SEC CIK
- 1850838
Omega Therapeutics financials before the delisting
The last 5 fiscal years Omega Therapeutics reported as a public company, fiscal year ending December.
OMGA revenue and net income
OMGA earnings per share
OMGA annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2023 | $3.09M | −$97.4M | −$1.81 |
| FY2022 | $2.07M | −$102.6M | −$2.14 |
| FY2021 | $144.0K | −$69.2M | −$7.37 |
| FY2020 | $0.00 | −$30.2M | −$0.79 |
| FY2019 | $0.00 | −$18.5M | −$0.37 |
Net income is GAAP. EPS is adjusted (non-GAAP) EPS, as reported.
Omega Therapeutics stock FAQ
What happened to Omega Therapeutics stock?
Omega Therapeutics was delisted from the Nasdaq in April 2025. The final close was $0.05 on April 28, 2025.
Can I still buy OMGA stock?
No. OMGA is no longer listed on the Nasdaq or any other U.S. exchange; it was removed on April 28, 2025.
What was the last price of OMGA?
OMGA last closed at $0.05 on April 28, 2025, which valued the company at about $7.90M.
How did Omega Therapeutics do in its last full fiscal year?
In fiscal 2023, its last full year as a public company, Omega Therapeutics reported revenue of $3.09M and net income of −$97.4M.
When did Omega Therapeutics go public?
Omega Therapeutics shares started trading on July 30, 2021.
OMGA no longer trades, so there is no live quote. The information on this page is for reference only and is not investment advice; see our disclaimer.